Compare ON Holding AG (ONON) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs TG Therapeutics Inc — how do they compare? ON Holding AG trades at $35.05 (market cap $11.38B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: ON Holding AG is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and TG Therapeutics Inc for 16 Days on average.
| ONON | TGTX | |
|---|---|---|
Market Cap | $11.38B | $8.16B |
Volume | 13,732,872 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $59.06 |
52-Week Low | $26.76 | $26.94 |
Typical Hold Time | 22 Days | 16 Days |
Enterprise Value | $10.54B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $34.99, up 5.33% with strong bullish momentum. The stock shows robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 beating expectations of $0.42. Technical indicators show bullish moving averages but overbought RSI conditions. Recent investor day announcements of a $1 billion buyback and ambitious 2029 targets have driven positive sentiment.
Outlook remains positive with analyst consensus at $42.26 target (21% upside) and 74% buy ratings. Key opportunities include DTC growth and margin expansion, while risks include execution on growth targets and competitive pressures in the athletic footwear sector. The stock trades at reasonable valuations with P/E of 24.02 and EV/EBITDA of 14.79.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
